 |
市場調查報告書
商品編碼
2075307
全球反義和RNAi療法市場：按技術、應用、給藥途徑和地區分類Global Antisense & RNAi Therapeutics Market, By Technology, By Application, By Route of Administration, By Geography |
||||||
全球反義和RNAi療法市場預計在2026年達到87.8億美元，預計2033年將達到243.7億美元。預計從2026年到2033年，該市場將以15.7%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 87.8億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 15.70% | 2033年市場規模預測： | 243.7億美元 |
反義和RNA干擾療法是一類利用自然發生的機制來標靶並抑制特定基因表現的藥物。它們透過與mRNA或基因組DNA高特異性結合發揮作用，從而抑制疾病相關蛋白的表達。由於其高特異性和低副作用，反義和RNA干擾療法市場正經歷顯著成長，使其有望應用於多種疾病的治療。目標疾病包括病毒感染疾病、癌症和遺傳性疾病。隨著眾多候選藥物進入臨床試驗階段，該市場在研發方面獲得了大量投資。此外，新型藥物遞送技術的開發正在拓展反義和RNA干擾療法的應用範圍，使其能夠用於治療以往難以治癒的疾病。
市場動態：
反義和RNA干擾療法是新型的核酸療法，旨在抑制致病基因的表達。它們透過與mRNA轉錄本結合，抑制翻譯或誘導mRNA分解發揮作用。這種選擇性定序不需要的基因的方法，使其在治療各種遺傳疾病、癌症和病毒感染疾病具有廣泛的應用前景。此技術利用與標靶mRNA互補的DNA、RNA或短的合成核酸鏈。全球反義和RNA干擾療法市場的發展主要受各種癌症、遺傳疾病和感染疾病在全球範圍內日益成長的發病率的推動。 RNA標靶藥物已在多種疾病的臨床試驗中展現出安全性和有效性，進一步促進了市場成長。此外，核苷酸藥物遞送系統（例如奈米顆粒）的不斷進步，正在提高這些療法的細胞內吸收率，並擴大其臨床應用。然而，藥物研發的高昂成本和潛在的脫靶效應仍然是市場相關人員面臨的挑戰。同時，主要品牌藥物專利即將到期，這將為學名藥創造機會。此外，針對慢性疾病的新型RNAi藥物平台的開發將進一步加速市場擴張。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球反義和 RNAi 療法市場中主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 這些公司從事受管制物質的研究、開發、生產和分銷。
- 透過利用本報告中提出的見解，各公司的行銷負責人和經營團隊將能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球反義和RNAi療法市場」報告的目標受群眾外包括產業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用分析全球反義和 RNAi 療法市場中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 藥物傳輸系統領域前景看好的創新
- 抑制因子
- RNA療法的高昂製造成本
- 機會
- 尚未開發的新興市場
- 促進因素
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特的分析
- 併購情景
第4章 反義與RNAi療法市場：依技術分類，2021-2033年
- RNA干擾
- 反義RNA
第5章 反義與RNAi療法市場：依應用領域分類，2021-2033年
- 遺傳性疾病
- 癌症
- 感染疾病
- 神經退化性疾病
- 心血管/代謝/腎臟疾病
- 眼科疾病
- 呼吸系統疾病
- 皮膚病
- 其他
第6章 反義與RNAi療法市場：依給藥途徑分類，2021-2033年
- 靜脈注射
- 鞘內注射
- 皮下注射
- 其他
第7章 反義與RNAi療法市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第8章 競爭情勢
- Benitec Biopharma Inc.
- Silence Therapeutics
- Ionis Pharmaceuticals, Inc
- Bio-Path Holdings Inc.
- Percheron Therapeutics Limited
- GSK plc
- Olix Pharmaceuticals, Inc.
- Sanofi
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma
第9章
- 調查方法
- 關於本公司
Global Antisense & RNAi Therapeutics Market is estimated to be valued at USD 8.78 Bn in 2026 and is expected to reach USD 24.37 Bn by 2033, growing at a compound annual growth rate (CAGR) of 15.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 15.70% | 2033 Value Projection: | USD 24.37 Bn |
Antisense & RNAi therapeutics refer to a class of drugs that use naturally occurring processes to target and inhibit the expression of specific genes. They work by binding to mRNA or genomic DNA with high specificity. This inhibits the expression of disease-associated proteins. The antisense & RNAi therapeutics market is growing substantially due to its potential to treat various conditions with high specificity and few side effects. These include viral infections, cancers, genetic disorders, and others. The market is witnessing significant investments in R&D as many drug candidates are progressing through clinical trials. The development of novel drug delivery techniques is also extending the potential of antisense & RNAi therapeutics to target previously undruggable diseases.
Market Dynamics:
Antisense and RNAi therapeutics are novel nucleic acid-based therapeutics designed to inhibit the expression of disease-causing genes. They work by binding to mRNA transcripts, preventing translation, or inducing mRNA degradation. This offers promise for treating various genetic disorders, cancers, and viral infections by selectively silencing unwanted genes. The technology utilizes short synthetic strands of nucleic acids such as DNA, RNA, or modified versions that are complementary to the target mRNA. The global antisense & RNAi therapeutics market is driven by the growing prevalence of various cancers, genetic disorders, and infectious diseases worldwide. RNA-targeting drugs have demonstrated safety and efficacy in clinical trials for various conditions, boosting market growth. Moreover, continuous advancements in nucleotide drug delivery systems, such as nanoparticles, have enhanced intracellular uptake of these therapeutics, expanding their clinical applications. However, high research and development costs associated with drug development and potential off-target effects are some of the challenges faced by market players. Meanwhile, the upcoming patent expiries of major brands will provide opportunities for generic versions. In addition, the development of novel RNAi drug platforms targeting chronic diseases will further stimulate market expansion.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antisense & RNAi therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc, Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma.
- These companies are involved in the research, development, manufacturing, and distribution of controlled substances
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antisense & RNAi therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antisense & RNAi therapeutics market
Detailed Segmentation:
- By Technology (Revenue, USD Bn, 2021 - 2033):
- RNA Interference
- Antisense RNA
- By Application (Revenue, USD Bn, 2021 - 2033)
- Genetic Disease
- Cancer
- Infectious Disease
- Neurodegenerative Disorders
- Cardio Metabolic & Renal Disorders
- Ocular Disorders
- Respiratory Disorders
- Skin Disorders
- Others
- By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Intravenous Injections
- Intrathecal Injections
- Subcutaneous Injections
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top companies in Antisense & RNAi Therapeutics Market
- Benitec Biopharma Inc.
- Silence Therapeutics
- Ionis Pharmaceuticals, Inc
- Bio-Path Holdings Inc.
- Percheron Therapeutics Limited
- GSK plc
- Olix Pharmaceuticals, Inc.
- Sanofi
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Technology
- Market Snippet, By Application
- Market Snippet, By Route of Administration
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Promising Innovations in Drug Delivery Systems
- Restraints
- High Manufacturing Cost of RNA Therapeutics
- Opportunities
- Untapped Emerging Markets
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Antisense & RNAi Therapeutics Market , By Technology, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- RNA Interference
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Antisense RNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Antisense & RNAi Therapeutics Market , By Application, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Genetic Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Infectious Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Neurodegenerative Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Cardio Metabolic & Renal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Ocular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Respiratory Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Skin Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
6. Antisense & RNAi Therapeutics Market , By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Intravenous Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Intrathecal Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Subcutaneous Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
7. Antisense & RNAi Therapeutics Market , By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022-2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region , 2021 - 2033,(US$ Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Benitec Biopharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Silence Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ionis Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bio-Path Holdings Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Percheron Therapeutics Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Olix Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alnylam Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Arbutus Biopharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
